Equibles does not estimate personal net worth.
Get an email with a short summary when Acumen Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ABOS alertsDaniel O'Connell is recorded as CEO at Acumen Pharmaceuticals, Inc. (ABOS). The newest filing on record that lists Daniel O'Connell as CEO at Acumen Pharmaceuticals, Inc. (ABOS) is dated April 23, 2026. The proxy statement of Acumen Pharmaceuticals, Inc. reports total compensation of $1,863,567 for Daniel O'Connell in fiscal 2025, including a base salary of $646,354. Disclosed compensation is on record for 6 fiscal years. Daniel O'Connell has spoken on 18 earnings calls and 3 other investor events across 1 company, most recently for Acumen Pharmaceuticals, Inc. on September 16, 2026. Acumen Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acumen Pharmaceuticals, Inc. includes Dr. George Golumbeski (Chairman and Board Member), Matthew Zuga (CFO), Russell Barton (COO) and 1 other.
“I'm pleased to provide you with an overview of our opportunity in the setup for Acumen and the value proposition strategy as we seek to bring better treatment options forward for people impacted by Alzheimer's disease.”
“I'm pleased to provide you with an overview of our opportunity in the setup for Acumen and the value proposition strategy as we seek to bring better treatment options forward for people impacted by Alzheimer's disease.”
“During the second quarter, our focus remained on discipline execution as we advance Soberna Tug towards the highly anticipated top line readout from our Phase II Altitude AD trial, which we continue to expect late this year.”
“So just to introduce Acumen real briefly, Acumen is a clinical stage company that is committed to advancing better treatment options for people living with Alzheimer's disease.”
“I ended last quarter's call by emphasizing the progress we've achieved with Sobernatug and our next-generation blood-brain barrier EVD candidates and highlighted the important work and upcoming milestones that lay ahead.”
Start not stated–present
Last confirmed April 23, 2026
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Acumen Pharmaceuticals, Inc. (ABOS) | Chief Executive Officer | $646,354 | $1,863,567 |
| 2024 | Acumen Pharmaceuticals, Inc. (ABOS) | Chief Executive Officer | $621,494 | $4,780,687 |
| 2023 | Acumen Pharmaceuticals, Inc. (ABOS) | Chief Executive Officer | $597,590 | $3,930,011 |
| 2022 | Acumen Pharmaceuticals, Inc. (ABOS) | Chief Executive Officer | $570,492 | $2,662,052 |
| 2021 | Acumen Pharmaceuticals, Inc. (ABOS) | President and Chief Executive Officer | $524,597 | $1,477,836 |
| 2020 | Acumen Pharmaceuticals, Inc. (ABOS) | President and Chief Executive Officer | $240,000 | $336,000 |
